- |||||||||| Fintepla (low-dose fenfluramine) / Zogenix
Serotonin and Focal Epilepsy: A Therapeutic Role? (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3922;
P2
Design/ We performed a pilot trial of PRX-00023 (Nalutozan), a high affinity 5HT1A agonist , in patients with focal epilepsy that showed promise in trials for anxiety and depression (Investigator initiated IND 110522; NCT01281956)...Subjects on benzodiazepines, phenobarbital, or phenytoin were excluded... Our two small pilot trials do not provide any suggestion that 5HT1A agonists have a treatment role in focal epilepsy.
- |||||||||| naluzotan (PRX-00023) / National Institutes of Health, Sawai Pharma
Trial termination, Trial primary completion date: PRX-00023 Therapy in Localization-Related Epilepsy (clinicaltrials.gov) - Oct 9, 2017
P2, N=12, Terminated,
Our two small pilot trials do not provide any suggestion that 5HT1A agonists have a treatment role in focal epilepsy. Enrolling by invitation --> Terminated | Trial primary completion date: Mar 2018 --> Oct 2017
- |||||||||| naluzotan (PRX-00023) / National Institutes of Health, Sawai Pharma
Trial primary completion date: PRX-00023 Therapy in Localization-Related Epilepsy (clinicaltrials.gov) - Sep 6, 2017
P2, N=12, Enrolling by invitation,
Enrolling by invitation --> Terminated | Trial primary completion date: Mar 2018 --> Oct 2017 Trial primary completion date: Aug 2017 --> Mar 2018
- |||||||||| naluzotan (PRX-00023) / National Institutes of Health, Sawai Pharma
Enrollment status, Enrollment change: PRX-00023 Therapy in Localization-Related Epilepsy (clinicaltrials.gov) - Apr 10, 2017
P2, N=12, Enrolling by invitation,
Trial primary completion date: Aug 2017 --> Mar 2018 Recruiting --> Enrolling by invitation | N=30 --> 12
- |||||||||| naluzotan (PRX-00023) / National Institutes of Health, Sawai Pharma
Trial primary completion date: PRX-00023 Therapy in Localization-Related Epilepsy (clinicaltrials.gov) - Apr 12, 2016
P2, N=30, Recruiting,
Recruiting --> Enrolling by invitation | N=30 --> 12 Trial primary completion date: May 2018 --> Aug 2017
- |||||||||| naluzotan (PRX-00023) / National Institutes of Health, Sawai Pharma
Enrollment status: PRX-00023 Therapy in Localization-Related Epilepsy (clinicaltrials.gov) - Sep 17, 2015
P2, N=30, Recruiting,
Trial primary completion date: May 2018 --> Aug 2017 Enrolling by invitation --> Recruiting
- |||||||||| naluzotan (PRX-00023) / National Institutes of Health, Sawai Pharma
Trial primary completion date: PRX-00023 Therapy in Localization-Related Epilepsy (clinicaltrials.gov) - Jun 11, 2015
P2, N=9, Enrolling by invitation,
Enrolling by invitation --> Recruiting Trial primary completion date: Aug 2015 --> May 2018
- |||||||||| naluzotan (PRX-00023) / National Institutes of Health, Sawai Pharma
Enrollment status, Enrollment change: PRX-00023 Therapy in Localization-Related Epilepsy (clinicaltrials.gov) - May 12, 2015
P2, N=9, Enrolling by invitation,
Trial primary completion date: Aug 2015 --> May 2018 Recruiting --> Enrolling by invitation | N=30 --> 9
|
